VMD approval for STARTECT

Posted on

(POM V) by the Veterinary Medicines Directorate.

From 25th August, Startect, which is manufactured by Zoetis, can be prescribed through agricultural merchants who employ pharmacists or suitably qualified persons (SQPs), as well as vets.

Temporary supply issues of Startect in Europe, mean farmers wishing to utilise the product, can do so with the help of their vet, who can import it under licence.

Startect
Startect is the only dual-active wormer on the UK market and is of major benefit to farmers in the fight against resistant worm populations.
It is the only wormer to contain two active ingredients from two different wormer groups and is more effective when compared to a wormer containing the constituents as a single active.
With both products active against roundworms, they have a higher efficacy compared to the constituents as a single active wormer, explained Zoetis vet Dr. Dave Armstrong.
“The benefits over a single active are vast because it not only kills worms resistant to other products, but used routinely, as part of a parasite control plan, can help delay wormer resistance. This will help protect your flock from drench failure now and into the future.”

STARTECT DUAL ACTIVE ORAL SOLUTION FOR SHEEP contains derquantel and abamectin. For the treatment and control of mixed gastrointestinal nematode infections and associated diseases of sheep. POM-VPS

For information about side effects, precautions, warnings and contra-indications for these products, please refer to the product packaging and package leaflet.

For further information please see the product’s SPC or contact Zoetis UK Limited, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS. www.zoetis.co.uk. Customer Support: 0845 300 8034.
Use medicines responsibly (www.noah.co.uk/responsible). Date of preparation: August 2017 AH588/17

About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.